key: cord-0968368-gtbegs4r
authors: Etter, M. M.; Martins, T.; Kulsvehagen, L.; Poessnecker, E.; Duchemin, W.; Hogan, S.; Diaz, G. S.; Mueller, J.; Chiappini, A.; Rychen, J.; Eberhard, N.; Melie-Garcia, L.; Keller, E.; Jelcic, I.; Siegemund, M.; Pargger, H.; Kuhle, J.; Oechtering, J.; Eich, C.; Tzankov, A.; Matter, M.; Yaldizli, O.; Lieb, J.; Psychogios, M. N.; Berkemeier, C.; Leuzinger, K.; Hirsch, H.; Granziera, C.; Proebstel, A.-K.; Hutter, G.
title: Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and signs of neurodegeneration: a prospective cross-sectional study
date: 2022-03-02
journal: nan
DOI: 10.1101/2022.02.18.22271039
sha: 6c288b890bc886f965716534147a1f463afd54c8
doc_id: 968368
cord_uid: gtbegs4r

Importance Growing evidence suggests that coronavirus disease 2019 (COVID-19) is associated with neurological sequelae. However, the underlying pathophysiological mechanisms resulting in central nervous system (CNS) derogation remain unclear. Objective To identify severity-dependent immune mechanisms in the cerebrospinal fluid (CSF) and plasma of COVID-19 patients and their association with brain imaging alterations. Design Prospective cross-sectional cohort study. Setting This study was performed from August 2020 to April 2021. Participants were enrolled in the outpatient clinics, hospital wards and intensive care units (ICU) of two clinical sites in Basel and Zurich, Switzerland. Participants Age >18 years and a positive SARS-CoV-2 test result were inclusion criteria. Potentially matching individuals were identified (n=310), of which 269 declined to participate and 1 did not match inclusion criteria. Paired CSF and plasma samples, as well as brain images, were acquired. The COVID-19 cohort (n=40; mean [SD] age, 54 [20] years; 17 women (42%)) was prospectively assorted by neurological symptom severity (classes I, II and III). Age/sex-matched inflammatory (n=25) and healthy (n=25) CSF and plasma control samples were obtained. For volumetric brain analysis, a healthy age/sex-matched control cohort (n=36) was established. Exposures Lumbar puncture, blood sampling and cranial MRI and/or CT. Main outcomes and measures Proteomics, standard parameters and antibody profiling of paired CSF and plasma samples in COVID-19 patients and controls. Brain imaging and gray matter volumetric analysis in association with biomarker profiles. Follow-up after 10-months. Results COVID-19 patients displayed a plasma cytokine storm but a non-inflammatory CSF profile. Class III patients displayed signs of blood-brain barrier (BBB) impairment and a polyclonal B cell response targeting self- and non-self antigens. Decreased regional brain volumes were present in COVID-19 patients and associated with specific CSF and plasma parameters. Conclusion and relevance Neuro-COVID class III patients had a strong, peripheral immune response resulting in (1) BBB impairment (2) ingress of (auto-)antibodies, (3) microglia activation and neuronal damage signatures. Our data point towards several potentially actionable targets that may be addressed to prevent COVID-19-related neurological sequelae. Trial registration

Proteomics, standard parameters and antibody profiling of paired CSF and plasma samples in COVID-19 patients and controls. Brain imaging and gray matter volumetric analysis in association with biomarker profiles. Follow-up after 10-months.

COVID-19 patients displayed a plasma cytokine storm but a non-inflammatory CSF profile. Class III patients displayed signs of blood-brain barrier (BBB) impairment and a polyclonal B cell response targeting self-and non-self antigens. Decreased regional brain volumes were present in COVID-19 patients and associated with specific CSF and plasma parameters.

Neuro-COVID class III patients had a strong, peripheral immune response resulting in (1) BBB impairment (2) ingress of (auto-)antibodies, (3) microglia activation and neuronal damage signatures. Our data point towards several potentially actionable targets that may be addressed to prevent COVID-19-related neurological sequelae.

The trial (NCT04472013) was registered on clinicaltrials.gov.

Word count of the abstract: 336/350 Introduction The prevalence of neurological symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, termed "Neuro-COVID", differs significantly between studies and can rarely be explained by direct virus effects ( brains. Additionally, formation of microglia and T cell nodules were detected across brain compartments as a site of greatest T cell and microglia activation (1) . Accordingly, cerebrospinal fluid (CSF) single-cell transcriptomics identified immune alterations in Neuro-COVID patients (2) .

Schwabenland (1) confirmed the presence of amyloid precursor protein deposits in COVID-19 brains, suggesting axonal damage as a result of immune activation.

However, SARS-CoV-2 RNA has rarely been detected in the CSF of COVID-19 patients, even in those displaying neurological symptoms. Moreover, new-onset humoral autoimmunity, including antineuronal antibodies, in COVID-19 individuals has been observed, even in the absence of increased conventional inflammatory CSF parameters and lacking evidence of inflammation upon neuroimaging (4) To understand the immune mechanisms responsible for different manifestations and severity classes of Neuro-COVID, we performed a prospective, in-depth characterization of immune mediators in the CSF and plasma of clinically wellcharacterized severity-stratified Neuro-COVID patients. Furthermore, we correlated these findings with imaging data, including magnetic resonance imaging (MRI), gray matter volume (GMV) and choroid plexus volume (CPV) analysis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint

We conducted a prospective, two-center, cross-sectional study (clinicaltrials.gov NCT04472013, IRB approval EKNZ 2020-01503) including COVID-19 patients from August 2020 to April 2021 at the Swiss University Hospitals of Basel and Zurich.

Inclusion criteria were age >18 years and a real-time quantitative PCR (qRT-PCR)positive SARS-CoV-2 infection. We screened 310 patients, of which 269 declined to participate and 1 did not meet inclusion criteria ( Figure 1A) . The 40 enrolled patients underwent detailed neurological examination and were subdivided into three Neuro-COVID severity classes at the time of their positive SARS-CoV-2 qRT-PCR test, referred to as Neuro-COVID class I (n=18), II (n=7) or III (n=15). Class I was defined by mild (e.g. anosmia, ageusia, headache, dizziness), class II by moderate (e.g. mono/para/quadriparesis, fatigue) and class III by severe symptoms (e.g., strokes, seizures, cognitive impairment) (6) . (Table 1) .

Retrospectively, biobanked age-and sex-matched CSF/plasma samples from patients with non-MS inflammatory neurologic disorders (n=25, IC) and healthy individuals (n=25, HC) served as controls (Table S1 ).

Following imputation, normalized protein expression values (NPX) were adjusted on the median age and sex. Kendall's Tau method correlated CSF/plasma expression levels. Group comparison was carried out using the Mann-Whitney-U test with a Benjamin-Hochberg (BH) correction for multiple testing.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) [20] years; 17 women [42%]) were enrolled in this cross-sectional analysis using a prospective study design ( Figure 1A) . Patient characteristics and follow-up details per severity class are summarized in Table 1 . COVID-19 patients were classified into absent/mild (n=18), moderate (n=7) and severe (n=15) Neuro-COVID classes I, II and III ( Figure 1A , Table 1, Table S2 ). Study interventions are summarized in Table 1 . Our long-term follow-up suggests that class II and III patients continued to be more often affected by neurological problems compared to class I. In class I, one third recovered without any long-term deficits. Notably, the mortality rate was high in class III patients: Five deceased, 3 of them during their hospital stay and 2 during the followup period.

Class III patients have an impaired blood-brain barrier (BBB) and a polyclonal B cell response In class III patients, CSF protein and lactate levels were significantly increased compared to class I/II (Figure 2A ). In contrast, CSF leukocytes were not elevated in COVID-19 patients, which signified ICs. Importantly, CSF glucose was increased even in class I and II patients versus (vs) HCs and was a significant discriminator between class III and ICs (Figure 2A) . Routine CSF parameters are described in Table 1 and Table S3 . In tendency, the CSF/plasma albumin ratio (Figure 2A ) as well as the total CSF IgG ( Figure S1B ) were higher in class III patients. In line with recent research (2), SARS-CoV-2 RNA was not detectable in the CSF. However, we were able to detect SARS-CoV-2 Spike (S) protein antibodies in 12 plasma and 3 CSF samples ( Figure 2C ), yet the antibody index (AI) pointed to a peripheral synthesis of these intrathecal antibodies (Table S3) . We could not detect reactivities against known CNS myelin antigens ( Figure S1 , CSF data not shown), but found elevated anti-dsDNA-IgG/IgA and anti-gut microbiota IgA responses in the CSF of class III compared to class I patients and ICs ( Figure 2C, Figure S1 ). This was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S4 ).

Most proteins were intrathecally (CSF/plasma ratio >0) secreted in ICs, whereas proteins in COVID-19 patients were peripherally synthesized (CSF/plasma ratio <0).

Of note, TRANCE/RANKL was the only intrathecally synthesized protein in class III compared to ICs ( Figure S3 , Table S5, Table S6 ).

Neuro-COVID class III features are manifestations of microglia regulation, neurodegeneration and BBB disruption As reported previously, plasma IL-6, IL-8, EN-RAGE, HGF, VEGFA, PD-L1 and TNFRSF12A levels were associated with COVID-19 severity (8) and distinct from ICs ( Figure S4A ), which lacked peripheral inflammation. Plasma TNFRSF11B, EZR and CCL23 were increased in class III vs ICs ( Figure S4A ). In contrast, plasma BMP-4, CLEC10A, CNTN5, GDF-8, NTRK2, ROBO2 and GDNFRα3 levels were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint lower in class III compared to ICs and class I patients ( Figure S4B ) (9) (10) (11) (12) (13) (14) (15) (16) . Further, compared to ICs, class III patients displayed higher plasma 4E-BP1 ( Figure S4C) .

HAGH was the only protein displaying higher plasma levels in class I vs class III ( Figure S4D ).

Several CSF soluble protein levels, particularly mediators of microglia regulation and neurodegeneration, including IL-8, MSR1, 4E-BP1, CD200R1, TNFRSF12A and EZR were increased in class III compared to class I ( Figure S4E ) (9)(10). However, only TNFRSF11B levels were both discriminating class III from ICs and gradually increasing among Neuro-COVID classes ( Figure S4F ). In class II, a T cell-mediated signature prevailed by CCL25, CD8A, GZMA, TNFRSF9 and IL2-RB, while some myeloid correlations overlapped between class I and II (15) (16) (17) . In class III, the pattern shifted to a neuronal damage signature encompassing CTSC, KYNU, TNFRSF12A, and CXCL9 (9, 10, 18, 19) .

To forecast severe Neuro-COVID, we attempted to identify biomarkers displaying strong correlations. Nine analytes (4 CSF and 5 plasma proteins) displayed an AUC-ROC score of >0.85, suggesting a high predictive power for class III development ( Figure 3D , Table S7 ). Among these, TNFRSF12A had a strong correlation (class III: 0.56, class II: -0.4, class I: 0.2), validating it as a predictive biomarker for severe Neuro-COVID.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022.

Neuro-COVID class III patients feature striking findings on brain imaging while most class I and II patients lack evidence of neuroinflammation Brain images of each class are depicted in Figure 4A -C. Detailed imaging findings are presented in Table S8 . The most frequent MRI findings were bilateral, multifocal hyperintense signal abnormalities on fluid-attenuated inversion recovery (FLAIR)/T2weighted (T2w) imaging (n=18, 56.3%; class I: n=5, 33.4%; class II: n=5, 83.4%; class III: n=11, 72.7%). These signal abnormalities were predominantly located in the periventricular region (13 patients, 40.6%) and the semioval center (16 patients, 50%). Further, diffusion-weighted imaging (DWI) changes were present in 4 patients GMV in olfactory pathway structures decrease in Neuro-COVID patients and negatively correlate with inflammatory CSF parameters Twenty brain regions displayed a smaller volume in the Neuro-COVID group compared to age/sex-matched HCs (Table S9) . Thereof, 81% corresponded to the olfactory/gustatory cortex's telencephalic connections, including the amygdala, entorhinal cortex, basal ganglia cingulate gyrus and orbitofrontal areas. However, this finding was not significant after FDR correction. Further, we found negative correlations between regional GMVs and CSF leukocyte count, protein levels and CSF/plasma albumin ratio (Table S10) in the Neuro-COVID group within 16 specific brain regions ( Figure S5 ). CPVs did not differ significantly between COVID-19 patients and controls, but we found marginally higher CPVs in class III compared to class I/II. However, these differences were not significant (data not shown).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint PD-L1 and HGF plasma levels are associated with decreased regional GMV, while GDF-8 and BMP-4 are neuroprotective in Neuro-COVID patients Additionally, we investigated the correlation of class-defining soluble CSF/plasma proteins and regional GMVs in regions with significantly lower volumes in COVID-19 patients (Table S9) . Plasma GDF-8 and BMP-4, implicated in neuroprotection and tissue reparatory responses (20, 21) were significantly lower in class III and II compared to class I ( Figure 4D, 4E, Figure S6 ). Conversely, PD-L1 and HGF were associated with decreased GMVs in Neuro-COVID patients ( Figure 4F, Figure S6 ).

PD-L1 and HGF plasma levels were higher in class III and II than in class I patients ( Figure 4G, Figure S6 ). Additional CSF and plasma proteins associated with particularly decreased and preserved GMVs underline the potential importance of COVID-19 dysregulated plasma and CSF proteins on brain structural changes ( Figure S7 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint

We identified Neuro-COVID-specific CSF and plasma alterations, providing insights into pathomechanisms underlying COVID-19-associated neurological sequelae.

Compared to previous analyses, we studied the associations of peripheral inflammation, neuroinflammation and neurological symptoms multidimensionally within prospectively stratified Neuro-COVID classes. Remarkably, our long-term follow-up suggests that class II and III patients continued to be severely affected by neurological problems, and mortality was high in class III patients.

In line with other studies (22), we found elevated CSF glucose and lactate levels in class III patients. Indeed, patients suffering from diabetes were more prevalent in class III ( Table 1) . The elevated lactate levels in class III potentially hint at cerebral hypoxia. However, class III patients had putative COVID-19-induced stroke or intracerebral hemorrhage, which may explain this finding.

Notably, we identified a class III-specific humoral CSF immune response encompassing enrichment of (total) IgG/IgA against self-(dsDNA) and non-self (BSA)

antigens. This finding is corroborated by distinct plasma B cell clusters and antibody reactivity profiles previously reported (5) . Certainly, antibody production predominantly took place in the plasma, pointing to an ingress of peripherally activated B cells/antibodies. In line with recent findings identifying new onset autoantibodies in patients with COVID-19 (4), our identification of elevated anti-dsDNA IgG, which are associated with cardiovascular symptoms in systemic lupus (23) , may provide a potential pathophysiological rationale for cardiovascular risk factors in severe COVID-19 (24) . Indeed, two out of four class lll patients with vascular complications had increased levels of anti-dsDNA IgG in the CSF.

Our observation of elevated anti-gut microbial IgA antibodies supports the evidence for gut barrier dysfunction in severe COVID-19 (25, 26) that may necessitate containment of gut microbiota translocated to the circulation/CSF (27) . In that regard, underlying conditions for microbiota dysbiosis, such as increased age, hypertension and diabetes have been observed in our class III cohort (Table 1) . Alternatively, trafficking of commensal-reactive regulatory B cells to sites of neuroinflammation as recently described (28, 29) may underlie these findings. Our observations shed new light on mucosal barrier disruption as a modulator of the peripheral host immune response. While we cannot exclude that the differences in class III are due to pre-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In line with prior research (7, 8) , we observed a class-incremental cytokine storm in plasma, but less prominent in CSF. Intriguingly, class III patients displayed a unique CSF protein pattern highlighting BBB disruption, microglia regulation and neuronal tissue damage. TNFRSF12A displayed a high CSF-plasma correlation and predictive value for class III, rendering it a predictive biomarker for severe Neuro-COVID given its involvement in BBB disruption during CNS immune cell recruitment (30, 31) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint Conversely, HGF, reported to mediate tissue-regenerative responses in COVID-19induced lung damage (8) , might serve as a counter-regulatory factor promoting neuroregeneration upon neuronal damage.

In contrast, lower plasma levels of neuroprotective GDF-8 (20) and BMP-4 (21), were associated with class II/III-related GMV loss, emphasizing the impact of COVID-19-induced soluble factors on distinct brain regions. Taken together, these GMV-associated CSF/plasma parameters may serve as targets to prevent long-term Neuro-COVID.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Finally, GMVs associations with distinctive biomarkers need cautious interpretation.

While we detected significant associations between class I and class II/III patients, confounding factors such as age or co-existing morbidities were not considered.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint

We provide a multiparametric framework of Neuro-COVID severity classifiers. Main determinants of severe Neuro-COVID are: (1) peripherally induced cytokine derangements, followed by (2) impaired BBB with ingressing polyreactive autoantibodies, (3) microglia reactivity and neuronal damage resulting in (4) potential GMV loss ( Figure S8) . Collectively, these data identified several targets with the potential to prevent COVID-19-related neurological sequelae.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint Acknowledgments We thank the patients and their relatives for their willingness to participate in this trial. We thank the medical and nursing staff of the University Hospital Basel

Intensive Care Unit and COVID-19 cohort wards, as well as the Neuroradiology and Neurosurgery Departments for their huge efforts in making this trial possible. We thank Hedda Wardemann for providing us with the polyreactive ED-38 antibody clone and Emma Allen-Vercoe for providing us with the microbial template.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Coronary artery disease, n (%) 4 (22.2%) 1 (14.3%) 1 (6.7%) Cancer of any type, n (%) 0 (0%) 1 (14.3%) 2 (13.3%) COPD, n (%) 0 (0%) 0 (0%) 0 (0%) Pre-existing neurological disorder Multiple sclerosis, n (%) 1 (5.6%) 0 (0%) 0 (0%) Underwent LP, n 0 --Underwent blood withdrawal, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint Speech/communication difficulties, n (%)* 0 (0%) 1 (14.3%) 0 (0%)

Change/loss of smell, n (%)* 0 (0%) 2 (28.6%) 0 (0%) Change/loss of taste, n (%)* 1 (5.9%) 1 (14.3%) 0 (0%) Muscle pain, n (%)* 2 (11.8%) 1 (14.3%) 0 (0%) Difficulties in daily activites, n (%)* 3 (17.6%) 2 (28.6%) 1 (33.3%)

Deceased, n (%) 1 (5.6%) 0 (0%) 5 (62.5%) In hospital during the ongoing study, n (%)* 0 (0%) -3 (37.5%) Table S6. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint Figure 4 : Routine brain imaging, regional GMV and association with different CSF and plasma analytes. 

Coronal cranial CT scan shows right temporo-occipital intracerebral hemorrhage (bottom right) (secondary to thrombosis of the right sigmoid sinus (not shown)). D)

Correlation plots demonstrating the regional brain volumes significantly correlating with BMP-4 plasma levels in Neuro-COVID patients. The Y-axis represents the regional brain volume values. The X-axis represents the marginalized NPX of the respective protein. None of the adjusted p-values was significant after BH-procedure. E) Boxplot representation of marginalized NPX of class I compared to merged class II+II plasma BMP-4 (Wilcoxon, p=0.011). F) Correlation plots demonstrating the regional brain volumes significantly correlating with PD-L1 plasma levels in Neuro-COVID patients. The Y-axis represents the regional brain volume values. The X-axis is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.02.18.22271039 doi: medRxiv preprint

Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions

Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid

A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms

Neurobiology of COVID-19

The signal pathways and treatment of cytokine storm in COVID-19

The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients

Cathepsin C promotes microglia M1 polarization and aggravates neuroinflammation via activation of Ca2+-dependent PKC/p38MAPK/NF-κB pathway

Genomic analysis of reactive astrogliosis

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection

Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients. Front Immunol

CMRF35-like molecule 1 (CLM-1) regulates eosinophil homeostasis by suppressing cellular chemotaxis

Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement

Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients

Single-cell landscape of immunological responses in patients with COVID-19

Developmental synaptic regulator, TWEAK/Fn14 signaling, is a determinant of synaptic function in models of stroke and neurodegeneration

The kynurenine pathway and neurodegenerative disease

Myostatin regulates pituitary development and hepatic IGF1

Activation of both transforming growth factor-β and bone morphogenetic protein signalling pathways upon traumatic brain injury restrains pro-inflammatory and boosts tissue reparatory responses of reactive astrocytes and microglia

Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients

Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation

Covid-19 and the cardiovascular system: a comprehensive review

Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-19 Severity? mBio

Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients

Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease

Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell

Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis

TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice

TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier

Interleukin-8 Released into the Cerebrospinal Fluid after Brain Injury is Associated with Blood-Brain Barrier Dysfunction and Nerve Growth Factor Production

VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain

Disruption of blood-brain barrier in Alzheimer disease pathogenesis. Tissue Barriers

Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection. Caliendo AM, editor

RANK/RANKL/OPG Signaling in the Brain: A Systematic Review of the Literature. Front Neurol

Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke

Differential transcriptional profiles identify microglial-and macrophage-specific gene markers expressed during virus-induced neuroinflammation

Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study

PD-L1 Dysregulation in COVID-19 Patients

Neurofascin as a novel target for autoantibody-mediated axonal injury

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus

Predominant autoantibody production by early human B cell precursors

Array programming with NumPy

Diffeomorphic registration using geodesic shooting and Gauss-Newton optimisation